Safety of Oral P2Y12 Inhibitors in Interventional Neuroradiology: Current Status and Perspectives

References

1. 1.↵
   1. Gorelick PB,
   2. Farooq MU

   . Advances in our understanding of “resistance” to antiplatelet agents for prevention of ischemic stroke. Stroke Res Treat 2013;2013:727842 doi:10.1155/2013/727842 pmid:23936730

   CrossRefPubMed
2. 2.↵
   1. Lee DH,
   2. Arat A,
   3. Morsi H, et al

   . Dual antiplatelet therapy monitoring for neurointerventional procedures using a point-of-care platelet function test: a single-center experience. AJNR Am J Neuroradiol 2008;29:1389–94 doi:10.3174/ajnr.A1070 pmid:18483190

   CrossRefPubMed
3. 3.↵
   1. Muller-Schunk S,
   2. Linn J,
   3. Peters N, et al

   . Monitoring of clopidogrel-related platelet inhibition: correlation of nonresponse with clinical outcome in supra-aortic stenting. AJNR Am J Neuroradiol 2008;29:786–91 doi:10.3174/ajnr.A0917 pmid:18223094

   Abstract/FREE Full Text
4. 4.↵
   1. Pandya DJ,
   2. Fitzsimmons BF,
   3. Wolfe TJ, et al

   . Measurement of antiplatelet inhibition during neurointerventional procedures: the effect of antithrombotic duration and loading dose. J Neuroimaging 2010;20:64–69 doi:10.1111/j.1552-6569.2008.00322.x pmid:19018951

   CrossRefPubMedWeb of Science
5. 5.↵
   1. Prabhakaran S,
   2. Wells KR,
   3. Lee VH, et al

   . Prevalence and risk factors for aspirin and clopidogrel resistance in cerebrovascular stenting. AJNR Am J Neuroradiol 2008;29:281–85 doi:10.3174/ajnr.A0818 pmid:17989373

   CrossRefPubMed
6. 6.↵
   1. Wagner H,
   2. Angiolillo DJ,
   3. ten Berg JM, et al

   . Higher body weight patients on clopidogrel maintenance therapy have lower active metabolite concentrations, lower levels of platelet inhibition, and higher rates of poor responders than low body weight patients. J Thromb Thrombolysis 2014;38:127–33 doi:10.1007/s11239-013-0987-8 pmid:24043374

   CrossRefPubMed
7. 7.↵
   1. Falcao FJ,
   2. Carvalho L,
   3. Chan M, et al

   . P2Y12 platelet receptors: importance in percutaneous coronary intervention. Arq Bras Cardiol 2013;101:277–82 doi:10.5935/abc.20130162 pmid:23917456

   CrossRefPubMed
8. 8.↵
   1. Wang Y,
   2. Wang Y,
   3. Zhao X, et al

   . Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med 2013;369:11–19 doi:10.1056/NEJMoa1215340 pmid:23803136

   CrossRefPubMedWeb of Science
9. 9.↵
   1. Johnston SC,
   2. Easton JD,
   3. Farrant M, et al

   . Clinical Research Collaboration, Neurological Emergencies Treatment Trials Network, and the POINT Investigators. Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA. N Engl J Med 2018;379:215–25 doi:10.1056/NEJMoa1800410 pmid:29766750

   CrossRefPubMed
10. 10.↵
    1. Hussein HM,
    2. Emiru T,
    3. Georgiadis AL, et al

    . Assessment of platelet inhibition by point-of-care testing in neuroendovascular procedures. AJNR Am J Neuroradiol 2013;34:700–06 doi:10.3174/ajnr.A2963 pmid:22422188

    Abstract/FREE Full Text
11. 11.↵
    1. Maldonado IL,
    2. Seris C,
    3. Mernes R, et al

    . Clopidogrel-related platelet inhibition: correlation with perioperative adverse events in neurointerventional procedures. The eJournal of the European Society of Minimally Invasive Neurological Therapy. 2014. http://ejmint.org/sites/default/files/pdf/original_article_1437000160.pdf. Accessed March 14, 2021
12. 12.↵
    1. Tan LA,
    2. Keigher KM,
    3. Munich SA, et al

    . Thromboembolic complications with Pipeline Embolization Device placement: impact of procedure time, number of stents and pre-procedure P2Y12 reaction unit (PRU) value. J NeuroIntervent Surg 2015;7:217–21 doi:10.1136/neurintsurg-2014-011111 pmid:24553344

    Abstract/FREE Full Text
13. 13.↵
    1. Gandhi CD,
    2. Bulsara KR,
    3. Fifi J, et al

    ; SNIS Standards and Guidelines Committee. Platelet function inhibitors and platelet function testing in neurointerventional procedures. J Neurointerv Surg 2014;6:567–77 doi:10.1136/neurintsurg-2014-011357 pmid:25056369

    FREE Full Text
14. 14.↵
    1. Nordeen JD,
    2. Patel AV,
    3. Darracott RM, et al

    . Clopidogrel resistance by P2Y12 platelet function testing in patients undergoing neuroendovascular procedures: incidence of ischemic and hemorrhagic complications. J Vasc Interv Neurol 2013;6:26–34 pmid:23826440

    PubMed
15. 15.↵
    1. Drazin D,
    2. Choulakian A,
    3. Nuno M, et al

    . Body weight: a risk factor for subtherapeutic antithrombotic therapy in neurovascular stenting. J Neurointerv Surg 2011;3:177–81 doi:10.1136/jnis.2010.004085 pmid:21990814

    Abstract/FREE Full Text
16. 16.↵
    1. Fifi JT,
    2. Brockington C,
    3. Narang J, et al

    . Clopidogrel resistance is associated with thromboembolic complications in patients undergoing neurovascular stenting. AJNR Am J Neuroradiol 2013;34:716–20 doi:10.3174/ajnr.A3405 pmid:23194833

    Abstract/FREE Full Text
17. 17.↵
    1. Flechtenmacher N,
    2. Kämmerer F,
    3. Dittmer R, et al

    . Clopidogrel resistance in neurovascular stenting: correlations between light transmission aggregometry, VerifyNow, and the Multiplate. AJNR Am J Neuroradiol 2015;36:1953–58 doi:10.3174/ajnr.A4388 pmid:26272977

    Abstract/FREE Full Text
18. 18.↵
    1. de Souza R,
    2. Pena MI,
    3. de Vasconcelos AV, et al

    . Carotid and vertebral artery stenting: REMAT data (Madre Teresa Registry). Revista Brasileira de Cardiologia Invasiva 2013;21:152–58 doi:10.1016/S2214-1235(15)30124-1

    CrossRef
19. 19.↵
    1. Asai T,
    2. Miyachi S,
    3. Izumi T, et al

    . Relationship between low response to clopidogrel and periprocedural ischemic events with coil embolization for intracranial aneurysms. J Neurointerv Surg 2016;8:752–55 doi:10.1136/neurintsurg-2015-011727 pmid:26109688

    Abstract/FREE Full Text
20. 20.↵
    1. Daou B,
    2. Starke RM,
    3. Chalouhi N, et al

    . P2Y12 reaction units: effect on hemorrhagic and thromboembolic complications in patients with cerebral aneurysms treated with the Pipeline Embolization Device. Neurosurgery 2016;78:27–33 doi:10.1227/NEU.0000000000000978 pmid:26571145

    CrossRefPubMed
21. 21.↵
    1. Nishi H,
    2. Nakahara I,
    3. Matsumoto S, et al

    . Platelet reactivity and hemorrhage risk in neurointerventional procedures under dual antiplatelet therapy. J Neurointerv Surg 2016;8:949–53 doi:10.1136/neurintsurg-2015-011844 pmid:26297788

    Abstract/FREE Full Text
22. 22.↵
    1. Holmes DR Jr.,
    2. Dehmer GJ,
    3. Kaul S, et al

    . Society for Cardiovascular Angiography Interventions, Society of Thoracic Surgeons, Writing Committee Members, ACCF/AHA Clopidogrel clinical alert: approaches to the FDA “boxed warning”: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the American Heart Association. Circulation 2010;122:537–57 doi:10.1161/CIR.0b013e3181ee08ed pmid:20585015

    FREE Full Text
23. 23.↵
    United States Food & Drug Administration. FDA Drug Safety Communication: Reduced effectiveness of Plavix (clopidogrel) in patients who are poor metabolizers of the drug. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fda-drug-safety-communication-reduced-effectiveness-plavix-clopidogrel-patients-who-are-poor. Accessed July 8, 2021
24. 24.↵
    1. Akbari SH,
    2. Reynolds MR,
    3. Kadkhodayan Y, et al

    . Hemorrhagic complications after prasugrel (Effient) therapy for vascular neurointerventional procedures. J Neurointerv Surg 2013;5:337–43 doi:10.1136/neurintsurg-2012-010334 pmid:22555594

    Abstract/FREE Full Text
25. 25.↵
    1. Atallah E,
    2. Saad H,
    3. Bekelis K, et al

    . The use of alternatives to clopidogrel in flow-diversion treatment with the Pipeline Embolization Device. J Neurosurg 2018;129:1130–35 doi:10.3171/2017.5.JNS162663 pmid:29219758

    CrossRefPubMed
26. 26.
    1. Choi HH,
    2. Cho YD,
    3. Han MH, et al

    . Antiplatelet premedication-free stent-assisted coil embolization in acutely ruptured aneurysms. World Neurosurg 2018;114:e1152–60 doi:10.1016/j.wneu.2018.03.164 pmid:29614363

    CrossRefPubMed
27. 27.↵
    1. Choi HH,
    2. Lee JJ,
    3. Cho YD, et al

    . Antiplatelet premedication for stent-assisted coil embolization of intracranial aneurysms: low-dose prasugrel vs clopidogrel. Neurosurgery 2018;83:981–88 doi:10.1093/neuros/nyx591 pmid:29301051

    CrossRefPubMed
28. 28.↵
    1. Delgado Almandoz JE,
    2. Crandall BM,
    3. Scholz JM, et al

    . Pre-procedure P2Y12 reaction units value predicts perioperative thromboembolic and hemorrhagic complications in patients with cerebral aneurysms treated with the Pipeline Embolization Device. J Neurointerv Surg 2013;5:iii3–10 doi:10.1136/neurintsurg-2012-010582 pmid:23314576

    Abstract/FREE Full Text
29. 29.↵
    1. Delgado Almandoz JE,
    2. Crandall BM,
    3. Scholz JM, et al

    . Last-recorded P2Y12 reaction units value is strongly associated with thromboembolic and hemorrhagic complications occurring up to 6 months after treatment in patients with cerebral aneurysms treated with the Pipeline Embolization Device. AJNR Am J Neuroradiol 2014;35:128–35 doi:10.3174/ajnr.A3621 pmid:23828107

    Abstract/FREE Full Text
30. 30.
    1. Ha EJ,
    2. Cho WS,
    3. Kim JE, et al

    . Prophylactic antiplatelet medication in endovascular treatment of intracranial aneurysms: low-dose prasugrel versus clopidogrel. AJNR Am J Neuroradiol 2016;37:2060–65 doi:10.3174/ajnr.A4864 pmid:27390320

    Abstract/FREE Full Text
31. 31.↵
    1. Higashiguchi S,
    2. Sadato A,
    3. Nakahara I, et al

    . Reduction of thromboembolic complications during the endovascular treatment of unruptured aneurysms by employing a tailored dual antiplatelet regimen using aspirin and prasugrel. J Neurointerv Surg 2021 Feb 25. [Epub ahead of print] doi:10.1136/neurintsurg-2020-016994 pmid:33632886

    Abstract/FREE Full Text
32. 32.
    1. Kurniawan RG,
    2. Song Y,
    3. Kwon B, et al

    . Tailored antiplatelet agent medication in clopidogrel hyporesponsive patients before stent-assisted coiling: single-center experience. Neuroradiology 2020;62:1709–15 doi:10.1007/s00234-020-02496-8 pmid:32661570

    CrossRefPubMed
33. 33.
    1. Lee D,
    2. Song Y,
    3. Han M, et al

    . Low-dose prasugrel in patients with resistance to clopidogrel for the treatment of cerebral aneurysms. Neurointervention 2018;13:124–27 doi:10.5469/neuroint.2018.01088 pmid:30196683

    CrossRefPubMed
34. 34.
    1. Oran I,
    2. Cinar C,
    3. Gok M, et al

    . Aggregometry response to half-dose prasugrel in flow-diverting stent implantation. Clin Neuroradiol 2020;30:463–69 doi:10.1007/s00062-019-00804-1 pmid:31165176

    CrossRefPubMed
35. 35.
    1. Parthasarathy R,
    2. Gupta V,
    3. Gupta A

    . Safety of prasugrel loading in ruptured blister like aneurysm treated with a Pipeline Device. Br J Radiol 2018;91:20170476 doi:10.1259/bjr.20170476 pmid:29509490

    CrossRefPubMed
36. 36.↵
    1. Stetler WR,
    2. Chaudhary N,
    3. Thompson BG, et al

    . Prasugrel is effective and safe for neurointerventional procedures. J Neurointerv Surg 2013;5:332–36 doi:10.1136/neurintsurg-2012-010302 pmid:22619468

    Abstract/FREE Full Text
37. 37.↵
    1. Sedat J,
    2. Chau Y,
    3. Gaudart J, et al

    . Prasugrel versus clopidogrel in stent-assisted coil embolization of unruptured intracranial aneurysms. Interv Neuroradiol 2017;23:52–59 doi:10.1177/1591019916669090 pmid:27760885

    CrossRefPubMed
38. 38.↵
    1. DeGrote JR,
    2. Olafson EM,
    3. Drofa A, et al

    . Ticagrelor and acetylsalicylic acid after placement of Pipeline Embolization Device for cerebral aneurysm: a case series. Can J Hosp Pharm 2019;71:349–55
39. 39.↵
    1. Hanel RA,
    2. Taussky P,
    3. Dixon T, et al

    . Safety and efficacy of ticagrelor for neuroendovascular procedures: a single-center initial experience. J Neuronterv Surg 2014;6:320–22 doi:10.1136/neurintsurg-2013-010699

    CrossRef
40. 40.↵
    1. Kang HS,
    2. Kwon BJ,
    3. Kim JE, et al

    . Preinterventional clopidogrel response variability for coil embolization of intracranial aneurysms: clinical implications. AJNR Am J Neuroradiol 2010;31:1206–10 doi:10.3174/ajnr.A2051 pmid:20223886

    Abstract/FREE Full Text
41. 41.↵
    1. Kim SH,
    2. Lee H,
    3. Kim SB, et al

    . Differences in thromboembolism after stent-assisted coiling for unruptured aneurysms between aspirin plus clopidogrel and ticagrelor. J Clin Neurosci 2020;82:128–33 doi:10.1016/j.jocn.2020.10.042 pmid:33317720

    CrossRefPubMed
42. 42.↵
    1. Mohammaden MH,
    2. English SW,
    3. Stapleton CJ, et al

    . Safety and efficacy of ticagrelor as single antiplatelet therapy in prevention of thromboembolic complications associated with the Pipeline Embolization Device (PED): multicenter experience. J Neurointerv Surg 2020;12:1113–16 doi:10.1136/neurintsurg-2020-015978 pmid:32471826

    Abstract/FREE Full Text
43. 43.↵
    1. Moore JM,
    2. Adeeb N,
    3. Shallwani H, et al

    . A multicenter cohort comparison study of the safety, efficacy, and cost of ticagrelor compared to clopidogrel in aneurysm flow diverter procedures. Neurosurgery 2017;81:665–71 doi:10.1093/neuros/nyx079 pmid:28475757

    CrossRefPubMed
44. 44.↵
    1. Park KY,
    2. Ozaki T,
    3. Kostynskyy A, et al

    . Ticagrelor versus clopidogrel in the dual antiplatelet regimen for intracranial stenting or flow-diverter treatment for unruptured cerebral aneurysms: a single-center cohort study. AJNR Am J Neuroradiol 2021;42:1638–44 doi:10.3174/ajnr.A7216 pmid:4244132

    Abstract/FREE Full Text
45. 45.↵
    1. Soize S,
    2. Foussier C,
    3. Manceau PF, et al

    . Comparison of two preventive dual antiplatelet regimens for unruptured intracranial aneurysm embolization with flow diverter/disrupter: a matched-cohort study comparing clopidogrel with ticagrelor. J Neuroradiol 2019;46:378–83 doi:10.1016/j.neurad.2019.01.094 pmid:30731144

    CrossRefPubMed
46. 46.↵
    1. Narata AP,
    2. Amelot A,
    3. Bibi R, et al

    . Dual antiplatelet therapy combining aspirin and ticagrelor for intracranial stenting procedures: a retrospective single center study of 154 consecutive patients with unruptured aneurysms. Neurosurgery 2019;84:77–83 doi:10.1093/neuros/nyy002 pmid:29490066

    CrossRefPubMed
47. 47.↵
    1. Scott DM,
    2. Norwood RM,
    3. Parra D

    . P2Y12 inhibitors in cardiovascular disease: focus on prasugrel. Ann Pharmacother 2009;43:64–76 doi:10.1345/aph.1G726 pmid:19050170

    CrossRefPubMed
48. 48.↵
    1. Capodanno D,
    2. Dharmashankar K,
    3. Angiolillo DJ

    . Mechanism of action and clinical development of ticagrelor, a novel platelet ADP P2Y12 receptor antagonist. Expert Rev Cardiovasc Ther 2010;8:151–18 doi:10.1586/erc.09.172 pmid:20136601

    CrossRefPubMed
49. 49.↵
    1. Maldonado IL,
    2. Machi P,
    3. Costalat V, et al

    . Neuroform stent-assisted coiling of unruptured intracranial aneurysms: short- and midterm results from a single-center experience with 68 patients. AJNR Am J Neuroradiol 2011;32:131–36 doi:10.3174/ajnr.A2245 pmid:20966053

    Abstract/FREE Full Text
50. 50.↵
    1. Gurbel PA,
    2. Bliden KP,
    3. Hiatt BL, et al

    . Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003;107:2908–13 doi:10.1161/01.CIR.0000072771.11429.83 pmid:12796140

    Abstract/FREE Full Text
51. 51.↵
    1. Koerner H,
    2. Derveaux C,
    3. Alexandrou M, et al

    . Do clopidogrel nonresponders have an increased risk of adverse events during supra-aortal angioplasty and stenting? Stroke Res Treat 2012;2012:904534 doi:10.1155/2012/904534 pmid:22577603

    CrossRefPubMed
52. 52.↵
    1. Angiolillo DJ,
    2. Fernandez-Ortiz A,
    3. Bernardo E, et al

    . Identification of low responders to a 300-mg clopidogrel loading dose in patients undergoing coronary stenting. Thromb Res 2005;115:101–08 doi:10.1016/j.thromres.2004.07.007 pmid:15567460

    CrossRefPubMedWeb of Science
53. 53.↵
    1. Karan V,
    2. Vyas D,
    3. Bohra V, et al

    . Ticagrelor use in Indian patients undergoing neuroendovascular procedures: a single center experience. Neurointervention 2019;14:125–30 doi:10.5469/neuroint.2019.00087 pmid:31387163

    CrossRefPubMed
54. 54.↵
    1. Yi HJ,
    2. Hwang G,
    3. Lee BH

    . Variability of platelet reactivity on antiplatelet therapy in neurointervention procedure. J Korean Neurosurg Soc 2019;62:3–9 doi:10.3340/jkns.2018.0151 pmid:30630291

    CrossRefPubMed
55. 55.↵
    1. Goh C,
    2. Churilov L,
    3. Mitchell P, et al

    . Clopidogrel hyper-response and bleeding risk in neurointerventional procedures. AJNR Am J Neuroradiol 2013;34:721–26 doi:10.3174/ajnr.A3418 pmid:23275598

    Abstract/FREE Full Text
56. 56.↵
    1. Nakagawa I,
    2. Park HS,
    3. Yokoyama S, et al

    . Influence of diabetes mellitus and cigarette smoking on variability of the clopidogrel-induced antiplatelet effect and efficacy of active management of the target P2Y12 reaction unit range in patients undergoing neurointerventional procedures. J J Stroke Cerebrovasc Dis.2016;25:163–71 doi:10.1016/j.jstrokecerebrovasdis.2015.09.010 pmid:26493334

    CrossRefPubMed
57. 57.↵
    1. Anderson CD,
    2. Biffi A,
    3. Greenberg SM, et al

    . Personalized approaches to clopidogrel therapy: are we there yet? Stroke 2010;41:2997–3002 doi:10.1161/STROKEAHA.110.594069 pmid:21030701

    Abstract/FREE Full Text
58. 58.↵
    1. Wallentin L

    . P2Y(12) inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use. Eur Heart J 2009;30:1964–77 doi:10.1093/eurheartj/ehp296 pmid:19633016

    CrossRefPubMedWeb of Science
59. 59.↵
    1. Sunderland N,
    2. Skroblin P,
    3. Barwari T, et al

    . MicroRNA biomarkers and platelet reactivity: the clot thickens. Circ Res 2017;120:418–35 doi:10.1161/CIRCRESAHA.116.309303 pmid:28104774

    Abstract/FREE Full Text
60. 60.↵
    1. Zhang YJ,
    2. Li MP,
    3. Tang J, et al

    . Pharmacokinetic and pharmacodynamic responses to clopidogrel: evidences and perspectives. Int J Environ Res Public Health 2017;14:301 doi:10.3390/ijerph14030301 pmid:28335443

    CrossRefPubMed
61. 61.↵
    1. Willeit P,
    2. Zampetaki A,
    3. Dudek K, et al

    . Circulating microRNAs as novel biomarkers for platelet activation. Circ Res 2013;112:595–600 doi:10.1161/CIRCRESAHA.111.300539 pmid:23283721

    Abstract/FREE Full Text
62. 62.↵
    1. Luchessi AD,
    2. Silbiger VN,
    3. Cerda A, et al

    . Increased clopidogrel response is associated with ABCC3 expression: a pilot study. Clin Chim Acta 2012;413:417– 21 doi:10.1016/j.cca.2011.10.018 pmid:22040781

    CrossRefPubMed
63. 63.↵
    1. Su J,
    2. Li X,
    3. Yu Q, et al

    . Association of P2Y12 gene promoter DNA methylation with the risk of clopidogrel resistance in coronary artery disease patients. Biomed Res Int 2014;2014:1–8 doi:10.1155/2014/408514 pmid:24745016

    CrossRefPubMed
64. 64.↵
    1. Neubauer H,
    2. Kaiser AF,
    3. Endres HG, et al

    . Tailored antiplatelet therapy can overcome clopidogrel and aspirin resistance: the BOchum CLopidogrel and Aspirin Plan (BOCLA-Plan) to improve antiplatelet therapy. BMC Med 2011;9:3 doi:10.1186/1741-7015-9-3 pmid:21226927

    CrossRefPubMed
65. 65.↵
    1. Gasparyan AY

    . Aspirin and clopidogrel resistance: methodological challenges and opportunities. Vasc Health Risk Manag 2010;6:109–12 doi:10.2147/vhrm.s9087 pmid:20448796

    CrossRefPubMed
66. 66.↵
    1. Farid NA,
    2. Payne CD,
    3. Small DS, et al

    . Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. Clin Pharmacol Ther 2007;81:735–41 doi:10.1038/sj.clpt.6100139 pmid:17361128

    CrossRefPubMedWeb of Science
67. 67.↵
    1. Siller-Matula JM,
    2. Trenk D,
    3. Krähenbühl S, et al

    . Clinical implications of drug-drug interactions with P2Y12 receptor inhibitors. J Thromb Haemost 2014;12:2–13 doi:10.1111/jth.12445 pmid:24406062

    CrossRefPubMed
68. 68.↵
    1. Gabriel SA,
    2. Beteli CB,
    3. Tanighuchi RS, et al

    . Aspirin resistance and atherothrombosis. Rev Bras Cir Cardiovasc 2007;22:96–103 doi:10.1590/s0102-76382007000100017 pmid:17992310

    CrossRefPubMed
69. 69.↵
    1. Judge HM,
    2. Patil SB,
    3. Buckland RJ, et al

    . Potentiation of clopidogrel active metabolite formation by rifampicin leads to greater P2Y12 receptor blockade and inhibition of platelet aggregation after clopidogrel: P2Y12 receptor blockade. J Thromb Haemost 2010;8:1820–27 doi:10.1111/j.1538-7836.2010.03925.x pmid:20492465

    CrossRefPubMed
70. 70.↵
    1. Bliden KP,
    2. DiChiara J,
    3. Lawal L, et al

    . The association of cigarette smoking with enhanced platelet inhibition by clopidogrel. J Am Coll Cardiol 2008;52:531–33 doi:10.1016/j.jacc.2008.04.045 pmid:18687246

    FREE Full Text
71. 71.↵
    1. Elsherbiny ME,
    2. Brocks DR

    . The ability of polycyclic aromatic hydrocarbons to alter physiological factors underlying drug disposition. Drug Metab Rev 2011;43:457–75 doi:10.3109/03602532.2011.596204 pmid:21823901

    CrossRefPubMed
72. 72.↵
    1. Desai NR,
    2. Mega JL,
    3. Jiang S, et al

    . Interaction between cigarette smoking and clinical benefit of clopidogrel. J Am Coll Cardiol 2009;53:1273–78 doi:10.1016/j.jacc.2008.12.044 pmid:19358940

    FREE Full Text
73. 73.↵
    1. Sibbing D,
    2. von Beckerath O,
    3. Schömig A, et al

    . Impact of body mass index on platelet aggregation after administration of a high loading dose of 600 mg of clopidogrel before percutaneous coronary intervention. Am Jo Cardiol 2007;100:203–05 doi:10.1016/j.amjcard.2007.02.081 pmid:17631070

    CrossRefPubMedWeb of Science
74. 74.↵
    1. Wong P,
    2. Tesoro E,
    3. Aletich V, et al

    . Accumetrics-based clopidogrel dosing in endovascular neurosurgery. Neurol Res 2015;37:998–1005 doi:10.1179/1743132815Y.0000000084 pmid:26344555

    CrossRefPubMed
75. 75.↵
    1. Ari H,
    2. Ozkan H,
    3. Karacinar A, et al

    . The EFFect of hIgh-dose ClopIdogrel treatmENT in patients with clopidogrel resistance (the EFFICIENT trial). Int J Cardiol 2012;157:374–80 doi:10.1016/j.ijcard.2010.12.083 pmid:21239075

    CrossRefPubMed
76. 76.↵
    1. Collet JP,
    2. Hulot JS,
    3. Anzaha G, et al

    . High doses of clopidogrel to overcome genetic resistance: the randomized crossover CLOVIS-2 (Clopidogrel and Response Variability Investigation Study 2). JACC Cardiovasc Interv 2011;4:392–402 doi:10.1016/j.jcin.2011.03.002 pmid:21511218

    Abstract/FREE Full Text
77. 77.↵
    1. Zhuo X,
    2. Zhuo B,
    3. Ouyang S, et al

    . Adverse clinical outcomes associated with double dose clopidogrel compared to the other antiplatelet regimens in patients with coronary artery disease: a systematic review and meta-analysis. BMC Pharmacol Toxicol 2018;19:54 doi:10.1186/s40360-018-0247-9 pmid:30176938

    CrossRefPubMed
78. 78.↵
    1. Shan J,
    2. Sun H

    . The discovery and development of prasugrel. Expert Opin Drug Discov 2013;8:897–905 doi:10.1517/17460441.2013.793668 pmid:23614463

    CrossRefPubMed
79. 79.↵
    1. Koike H,
    2. Asai F,
    3. Sugidachi A, et al

    . Hydropyridine derivatives having antithrombotic activity. CA2077695 1993
80. 80.↵
    Center for Drug Evaluation and Research. EFFIENT™ Approval letter. (NDA 22-307). https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2009/022307s000_ltr.pdf. Accessed July 8, 2021
81. 81.↵
    1. Norgard NB,
    2. Dinicolantonio JJ

    . Clopidogrel, prasugrel, or ticagrelor? A practical guide to use of antiplatelet agents in patients with acute coronary syndromes. Postgrad Med 2013;125:91–102 doi:10.3810/pgm.2013.07.2682 pmid:23933898

    CrossRefPubMed
82. 82.↵
    1. Wiviott SD,
    2. Braunwald E,
    3. Angiolillo DJ, et al

    . Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38. Circulation 2008;118:1626–36 doi:10.1161/CIRCULATIONAHA.108.791061 pmid:18757948

    Abstract/FREE Full Text
83. 83.↵
    1. Montalescot G,
    2. Wiviott SD,
    3. Braunwald E, et al

    ; TRITON-TIMI 38 Investigators. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet 2009;373:723–31 doi:10.1016/S0140-6736(09)60441-4 pmid:19249633

    CrossRefPubMedWeb of Science
84. 84.↵
    1. Wiviott SD,
    2. Braunwald E,
    3. McCabe CH, et al

    . Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001–15 doi:10.1056/NEJMoa0706482 pmid:17982182

    CrossRefPubMedWeb of Science
85. 85.↵
    1. Ogawa A,
    2. Toyoda K,
    3. Kitagawa K, et al

    ; PRASTRO-I Study Group. Comparison of prasugrel and clopidogrel in patients with non-cardioembolic ischaemic stroke: a phase 3, randomised, non-inferiority trial (PRASTRO-I). Lancet Neurol 2019;18:238–47 doi:10.1016/S1474-4422(18)30449-6 pmid:30784555

    CrossRefPubMed
86. 86.↵
    1. Kitagawa K,
    2. Toyoda K,
    3. Kitazono T, et al

    . Safety and efficacy of prasugrel in elderly/low body weight Japanese patients with ischemic stroke: randomized PRASTRO-II. Cerebrovasc Dis 2020;49:152–59 doi:10.1159/000506825 pmid:32208397

    CrossRefPubMed
87. 87.↵
    United States Food & Drug Administration. Highlights of prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022307s018lbl.pdf. Accessed July 8, 2021
88. 88.↵
    1. Byrne JV

    . Tutorials in Endovascular Neurosurgery and Interventional Neuroradiology. Springer International Publishing; 2017
89. 89.↵
    1. Jeong YH,
    2. Bliden KP,
    3. Antonino MJ, et al

    . Usefulness of the VerifyNow P2Y12 assay to evaluate the antiplatelet effects of ticagrelor and clopidogrel therapies. Am Heart J 2012;164:35–42 doi:10.1016/j.ahj.2012.03.022 pmid:22795280

    CrossRefPubMedWeb of Science
90. 90.↵
    1. Gurbel PA,
    2. Bliden KP,
    3. Butler K, et al

    . Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study. Circulation 2010;121:1188–99 doi:10.1161/CIRCULATIONAHA.109.919456 pmid:20194878

    Abstract/FREE Full Text
91. 91.↵
    1. Dobesh PP,
    2. Oestreich JH

    . Ticagrelor: pharmacokinetics, pharmacodynamics, clinical efficacy, and safety. Pharmacotherapy 2014;34:1077–90 doi:10.1002/phar.1477 pmid:25164528

    CrossRefPubMed
92. 92.↵
    1. Teng R,
    2. Mitchell PD,
    3. Butler KA

    . Pharmacokinetic interaction studies of co-administration of ticagrelor and atorvastatin or simvastatin in healthy volunteers. Eur J Clin Pharmacol 2013;69:477–87 doi:10.1007/s00228-012-1369-4 pmid:22922682

    CrossRefPubMed
93. 93.↵
    1. Gurbel PA,
    2. Bliden KP,
    3. Butler K, et al

    . Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET Study. Circulation 2009;120:2577–85 doi:10.1161/CIRCULATIONAHA.109.912550 pmid:19923168

    Abstract/FREE Full Text
94. 94.↵
    1. James SK,
    2. Roe MT,
    3. Cannon CP, et al

    ; PLATO Study Group. Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial. BMJ 2011;342:d3527 doi:10.1136/bmj.d3527 pmid:21685437

    Abstract/FREE Full Text
95. 95.↵
    1. Wallentin L,
    2. Becker RC,
    3. Budaj A, et al

    . Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045–57 doi:10.1056/NEJMoa0904327 pmid:19717846

    CrossRefPubMedWeb of Science
96. 96.↵
    1. Johnston SC,
    2. Amarenco P,
    3. Albers GW, et al

    ; SOCRATES Steering Committee and Investigators. Ticagrelor versus aspirin in acute stroke or transient ischemic attack. N Engl J Med 2016;375:35–43 doi:10.1056/NEJMoa1603060 pmid:27160892

    CrossRefPubMed
97. 97.↵
    1. Johnston SC,
    2. Amarenco P,
    3. Denison H, et al

    ; THALES Investigators. Ticagrelor and aspirin or aspirin alone in acute ischemic stroke or TIA. N Engl J Med 2020;383:207–17 doi:10.1056/NEJMoa1916870 pmid:32668111

    CrossRefPubMed
98. 98.↵
    1. Godier A,
    2. Taylor G,
    3. Gaussem P

    . Inefficacy of platelet transfusion to reverse ticagrelor. N Engl J Med 2015;372:196–97 doi:10.1056/NEJMc1409373 pmid:25564918

    CrossRefPubMed
99. 99.↵
    1. Bertling A,
    2. Fender AC,
    3. Schungel L, et al

    . Reversibility of platelet P2Y12 inhibition by platelet supplementation: ex vivo and in vitro comparisons of prasugrel, clopidogrel and ticagrelor. J Thromb Haemost 2018;16:1089–98 doi:10.1111/jth.14014 pmid:29582544

    CrossRefPubMed
100. 100.↵
     1. Bhatt DL,
     2. Pollack CV,
     3. Weitz JI, et al

     . Antibody-based ticagrelor reversal agent in healthy volunteers. N Engl J Med 2019;380:1825–33 doi:10.1056/NEJMoa1901778 pmid:30883047

     CrossRefPubMed